Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) announced that it has received full regulato...
Gesynta Pharma AB, a clinical-stage biotech company developing vipoglanstat, a non-hormonal, non-opioid therapy that could transform the standard of care f...
Building on Omvoh's approved use and durable efficacy in adults, Lilly plans to submit these data to global regulators to support a potential label expansi...
Topline results to be presented by Federico Cappuzzo, MD, PhD, on October 25, 2026, at the Annual Meeting of the European Society for Medical Oncology (E...
Three-year data from the EVX-01 phase 2 trial in patients with advanced melanoma to be presented at the ESMO 2026 Congress Data supplements unprecedente...
Managing motor fluctuations and dyskinesia remains a significant challenge for people living with advanced Parkinson's disease, despite advances in existin...
FDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement...
Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced that the first patient has been dosed in an open-label, m...
AN4035, a first-in-class investigational pan-RAS(ON) inhibitor-based ADC, will be evaluated as monotherapy and in combination with cetuximab in the ongoing...
Salvia BioElectronics, a clinical-stage medical device company pioneering a novel neuromodulation therapy for people with resistant migraine, announced tha...
Eclipse Life Sciences, Inc., a privately held clinical-stage biopharmaceutical company developing next-generation therapies for retinal diseases, announced...
New designation expands on first Fast Track Designation in TMB-H colorectal cancer and is supported by monotherapy responses across m...
Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjug...
As demand for injectable therapies grows and manufacturing requirements become more complex, Vetter Pharma is expanding its global fill-finish network to...
© 2026 Biopharma Boardroom. All Rights Reserved.
